CompoAtlas

NeuroMood Pure Pack

In vendita sul mercato statunitense (secondo il DSLD)

Pure Encapsulations, integratore alimentare del mercato statunitense

NeuroMood Pure Pack (Pure Encapsulations), integratore alimentare au code-barres 766298016252, è descritto dalla sua etichetta per il mercato statunitense. Se venduto in Francia, sarebbe interessato da 5 punti della normativa francese o europea, illustrati di seguito. Le dosi di folates, niacine, vitamine A non vengono confrontate: le loro unità statunitensi dipendono dalla forma. La formula venduta in Europa con lo stesso nome può essere diversa.

Etichetta ufficiale. Dietary Supplement Label Database (DSLD), National Institutes of Health statunitensi (NIH): etichette in vendita o ritirate dal mercato, consultato il 27 ottobre 2026.

Fonte: NIH, Office of Dietary Supplements, Dietary Supplement Label Database (CC0); etichette del mercato statunitense.

Se questo prodotto fosse venduto in Francia

Una dose giornaliera si calcola solo se l’etichetta indica il numero massimo di assunzioni e un’unità di massa (o unità internazionali per la vitamina D). Le quantità provengono dall’etichetta, non da un’analisi. Negli Stati Uniti, l’etichetta presenta il prodotto come «dietary supplement»; in Francia, un prodotto di questo tipo può rientrare in un’altra categoria (per esempio una polvere per sportivi) e le dosi massime degli integratori alimentari non si applicano.

Composizione dell’etichetta

Marca
Pure Encapsulations
Codice a barre
766298016252
Forma
Altro (per esempio una bustina per infusione)
Un’assunzione
5 capsule
Assunzioni
al massimo 1 assunzione al giorno
Altri ingredienti (in inglese, come scritti)

Testo originale in inglese.

Vegetarian Capsule, Gelatin Capsule, hypoallergenic Plant Fiber, Ascorbyl Palmitate, Potato Starch

Dietary Supplement Label Database (DSLD), National Institutes of Health statunitensi (NIH): etichette in vendita o ritirate dal mercato ·

Ingrediente (come scritto, in inglese)CategoriaPer assunzione
CaloriesAltro10 Calorie(s)
Total FatLipide1 Gram(s)
CholesterolLipidenon indicata
Vitamin AVitamina1.125 µg
Vitamin CVitamina180 mg
Vitamin DVitamina50 µg
Vitamin EVitamina20 mg
ThiamineVitamina3 mg
RiboflavinVitamina3 mg
NiacinVitamina20 mg
Vitamin B6Vitamina7,5 mg
FolateVitamina1.083 µg EFA (equivalenti di folato alimentare)
L-5-MTHFVitamina650 µg
Vitamin B12Vitamina500 µg
BiotinVitamina300 µg
Pantothenic AcidVitamina10 mg
CholineVitamina25 mg
IodineMinerale150 µg
MagnesiumMinerale120 mg
ZincMinerale30 mg
SeleniumMinerale70 µg
ManganeseMinerale2 mg
ChromiumMinerale200 µg
MolybdenumAltra sostanza75 µg
Boron GlycinateMinerale1 mg
InositolAltra sostanza25 mg
Coenzyme Q10Altra sostanza50 mg
Alpha Lipoic AcidAltra sostanza50 mg
FloraGLO LuteinAltra sostanza3 mg
ZeaxanthinAltra sostanza500 µg
LycopeneAltra sostanza500 µg
DL-PhenylalanineAmminoacido350 mg
5-HTPAmminoacido50 mg
Meriva Turmeric Phytosome (Curcuma longa)Pianta125 mg
QuercetinAltra sostanza50 mg
TaurineAltra sostanza1.000 mg
Fish Oil concentrateLipide1.000 mg
Eicosapentaenoic AcidAcido grasso300 mg
Docosahexaenoic AcidAcido grasso200 mg

Etichetta presentata: Etichetta ufficiale. Si privilegiano le etichette in vendita, poi la più recente per lo stesso stato.

Altre versioni di questa etichetta

Le differenze qui sotto descrivono ogni altra versione rispetto all’etichetta presentata nella scheda. Riguardano le righe degli ingredienti attivi e le quantità per assunzione come scritte. Le quantità mancanti non vengono stimate e le unità diverse non vengono convertite. Le date sono quelle di ingresso nel DSLD, non necessariamente di un cambiamento della formula.

Queste informazioni riprendono l’etichetta statunitense registrata dagli Istituti nazionali di sanità degli Stati Uniti (NIH). Non dicono se il prodotto sia efficace e non sostituiscono il parere di un medico o farmacista, in particolare in gravidanza o durante un trattamento.

Avvertenze ufficiali (Health Canada)

Health Canada pubblica avvertenze su questi ingredienti:

  • Vitamin D
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    VITAMIN D (>1,000 - 2,500 IU)

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Condizione di applicazione: All products except products containing zinc sourced from picolinate requiring a contraindication.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Condizione di applicazione: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney disorders (NIH 2024; BfR 2020).

    Fonti citate da Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other supplements or products containing vitamin D or vitamin D analogues.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any medications including antacids, anticonvulsants, digoxin, cholestyramine, colestipol, mineral oil, steroids, statins or thiazide diuretics (NNHPD 2021; BfR 2020).

    Fonti citate da Health Canada (3)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NNHPD 2021. Natural and Non-Prescription Health Products Directorate. Internal evidence and HC's product monographs.
    • DPSNSO 2021. Direction des produits de santé naturels et sans ordonnance. Preuves internes et monographies de produits internes de SC.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to determine if you would benefit from additional vitamin D as 15-20 mcg (600-800 IU) of vitamin D per day is an adequate quantity for most individuals.

    Si applica ai prodotti: containing vitamin K2.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (NNHPD 2026).

    Fonti citate da Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Si applica ai prodotti: providing 25-34 mg of zinc per day for adults 18 years or 31-50 mg of zinc per day for adults 19 years and older.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are unsure whether you are taking enough copper as zinc supplementation can cause a copper deficiency (NNHPD 2026).

    Fonti citate da Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Controindicazioni

    Condizione di applicazione: All products.

    Do not use if you have hypercalcemia and/or hypercalciuria (NIH 2024; BfR 2020).

    Fonti citate da Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Si applica ai prodotti: containing zinc sourced from picolinate.

    Do not use if you are pregnant or breastfeeding (NNHPD 2026).

    Fonti citate da Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Reazioni avverse note

    Condizione di applicazione: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if the following early symptoms of hypercalcemia occur: weakness, fatigue, drowsiness, headache, lack of appetite, dry mouth, metallic taste, nausea, vomiting, vertigo, ringing in the ears, lack of coordination and muscle weakness or if you develop any other symptom (NIH 2024; BfR 2020).

    Fonti citate da Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Si applica ai prodotti: providing more than 350 mg of magnesium per day.

    When using this product you may experience diarrhea (NNHPD 2026).

    Fonti citate da Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Monografia di Health Canada del 26 giugno 2026

  • Coenzyme Q10
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    Coenzyme Q10 (UBIQUINONE-10)

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Condizione di applicazione: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).

    Fonti citate da Health Canada (2)
    • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analisi
    • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Studio randomizzato

    Si applica ai prodotti: providing more than 100 mg of Coenzyme Q10 per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    Fonti citate da Health Canada (3)
    • Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Studio randomizzato
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Caso clinico
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Caso clinico

    Condizione di applicazione: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Monografia di Health Canada del 31 gennaio 2025

  • 5-HTP
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    5-HTP

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Condizione di applicazione: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking carbidopa or health products with serotonergic activity such as mood balance supplements, cough medication containing dextromethorphan, pain killers or medications for nausea or migraine (Mayo Clinic Staff 2022; Patel and Marzella 2017; Turner et al 2006).

    Fonti citate da Health Canada (3)
    • Mayo Clinic Staff. Serotonin Syndrome. Rochester (MN): Mayo Foundation for Medical Education and Research; 2022. [Accessed 2023 March 07]. Available from: https://www.mayoclinic.org/diseases-conditions/serotonin-syndrome/symptoms-causes/syc-20354758.
    • Patel YA, Marzella N. Dietary supplement-drug interaction-induced serotonin syndrome progressing to acute compartment syndrome. American Journal of Case Reports 2017; 18:926-930. PubMed Caso clinico
    • Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology & Therapeutics 2006;109(3):325-338. PubMed Articolo di revisione

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    When using this product exercise caution while driving or using machinery, as you may experience drowsiness (Berardi et al. 2002).

    Fonti citate da Health Canada (1)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollings CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condizione di applicazione: All uses (excluding weight management).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Condizione di applicazione: Weight management.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.

    Condizione di applicazione: Healthy mood balance; Fibromyalgia symptoms.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a psychological disorder such as anxiety or depression.

    Controindicazioni

    Condizione di applicazione: All uses.

    Do not use if you have scleroderma (Lampert et al. 1992; Sternberg et al. 1980).

    Fonti citate da Health Canada (2)
    • Lampert A, Joly P, Thomine E, Ortoli JC, Lauret P. [Scleroderma-like syndrome with bullous morphea during treatment with 5-hydroxytryptophan, carbidopa and flunitrazepam]. Annales de Dermatologie et de Vénéréologie 1992;119(3):209-211 (in French). PubMed Caso clinico
    • Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. New England Journal of Medicine 1980;303(14):782-787. PubMed Studio clinico

    Do not use if you are taking antidepressants (Mayo Clinic Staff 2022; Patel and Marzella 2017).

    Fonti citate da Health Canada (2)
    • Mayo Clinic Staff. Serotonin Syndrome. Rochester (MN): Mayo Foundation for Medical Education and Research; 2022. [Accessed 2023 March 07]. Available from: https://www.mayoclinic.org/diseases-conditions/serotonin-syndrome/symptoms-causes/syc-20354758.
    • Patel YA, Marzella N. Dietary supplement-drug interaction-induced serotonin syndrome progressing to acute compartment syndrome. American Journal of Case Reports 2017; 18:926-930. PubMed Caso clinico

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    Condizione di applicazione: Weight management.

    Do not use if you are pregnant (HC 2010).

    Fonti citate da Health Canada (2)
    • HC 2010: Health Canada: Prenatal Nutrition Guidelines for health Professionals: Gestational weight gain [Accessed 2024 April 7]. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-eng.pdf
    • SC 2010 : Santé Canada : Lignes directrices sur la nutrition pendant la grossesse à l'intention des professionnels de la santé : Gain de poids pendant la grossesse. [Consulté le 7 avril 2024]. Disponible à : https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-fra.pdf

    Reazioni avverse note

    When using this product you may experience gastrointestinal discomfort/disturbances (Turner et al. 2006; Byerley et al. 1987).

    Fonti citate da Health Canada (2)
    • Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. Journal of Clinical Psychopharmacology 1987;7(3):127-137. PubMed Studio clinico
    • Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology & Therapeutics 2006;109(3):325-338. PubMed Articolo di revisione

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience skin hardening, pain or stiffness of muscles or joints, tremors, agitation/confusion, or an increased heart rate (Boyer 2023; Varga 2023; Mayo Clinic Staff 2022; Patel and Marzella 2017; Das et al. 2004; Erner et al. 2003; Lampert et al. 1992; Sternberg et al. 1980).

    Fonti citate da Health Canada (8)
    • Boyer EW. Serotonin syndrome (serotonin toxicity). UpToDate 2023 [Accessed 2023 October 18]. Available from: Available from : https://www.uptodate.com/.
    • Das YT, Bagchi M, Bagchi D, Preuss HG. Safety of 5-hydroxy-L-tryptophan. Toxicology Letters 2004;150(1):111-122. PubMed Caso clinico
    • Erner RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin Syndrome and Other Serotonergic Disorders. Pain Medicine 2003;4(1): 63-74.
    • Lampert A, Joly P, Thomine E, Ortoli JC, Lauret P. [Scleroderma-like syndrome with bullous morphea during treatment with 5-hydroxytryptophan, carbidopa and flunitrazepam]. Annales de Dermatologie et de Vénéréologie 1992;119(3):209-211 (in French). PubMed Caso clinico
    • Mayo Clinic Staff. Serotonin Syndrome. Rochester (MN): Mayo Foundation for Medical Education and Research; 2022. [Accessed 2023 March 07]. Available from: https://www.mayoclinic.org/diseases-conditions/serotonin-syndrome/symptoms-causes/syc-20354758.
    • Patel YA, Marzella N. Dietary supplement-drug interaction-induced serotonin syndrome progressing to acute compartment syndrome. American Journal of Case Reports 2017; 18:926-930. PubMed Caso clinico
    • Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. New England Journal of Medicine 1980;303(14):782-787. PubMed Studio clinico
    • Varga J. Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults. UpToDate 2023 [Accessed 2023 October 18]. Available from : https://www.uptodate.com/.

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    Monografia di Health Canada del 28 agosto 2024

  • Meriva Turmeric Phytosome
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    TURMERIC - CURCUMA LONGA - Oral

    Via di somministrazione: Oral (ESCOP 2003; Blumenthal et al. 2000)

    Precauzioni e avvertenze

    Condizione di applicazione: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (ESCOP 2003; Brinker 2001; McGuffin et al. 1997).

    Fonti citate da Health Canada (2)
    • ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder (HC 2025; EMA 2018; Brinker 2010; ESCOP 2003; McGuffin et al. 1997).

    Fonti citate da Health Canada (6)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2018. European Medicines Agency. European Union herbal monograph on Curcuma longa L., rhizome. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 25 September 2018. [Accessed 2023 October 14] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf
    • ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).

    Fonti citate da Health Canada (2)
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).

    Fonti citate da Health Canada (2)
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Condizione di applicazione: All uses except for Source of antioxidants and Hepatoprotectant.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografia di Health Canada del 26 settembre 2025

    Turmeric -CURCUMA LONGA - Topical

    Precauzioni e avvertenze

    For external use only.

    When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.

    Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.

    Controindicazioni

    Do not use on deep or puncture wounds, animal bites or serious burns.

    Monografia di Health Canada del 28 febbraio 2025

  • Taurine
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    TAURINE

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Lopez Ramon et al. 2007; Seghieri et al. 2007).

    Fonti citate da Health Canada (2)
    • López Ramón Y Cajal C, Ocampo Martínez R, Couceiro Naveira E, Martínez M. Amino acids in amniotic fluid in the 15th-16th weeks of gestation and preterm labor. The Journal of Maternal-Fetal & Neonatal Medicine: the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2007;20(3):225-231.
    • Seghieri G, Tesi F, Bianchi L, Loizzo A, Saccomanni G, Ghirlanda G, Anichini R, Franconi F. Taurine in women with a history of gestational diabetes. Diabetes Research and Clinical Practice 2007;76(2):187-192. PubMed

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    Monografia di Health Canada del 30 gennaio 2026

Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.

Elenco dichiarato il (registro: Dietary Supplement Label Database (DSLD), National Institutes of Health statunitensi (NIH): etichette in vendita o ritirate dal mercato).

Fotografare la confezione

Marca : Pure Encapsulations

Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.

Elenco rilevato nel 2021. Fotografi la confezione per verificare eventuali modifiche.

Invio per analizzare, Maiusc+Invio per una nuova riga